Literature DB >> 28776198

Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Geisa Cristina da Silva Alves1,2, Samuel Dutra da Silva3, Virginia Paula Frade3, Danielle Rodrigues3, André de Oliveira Baldoni3, Whocely Victor de Castro3, Cristina Sanches3.   

Abstract

OBJECTIVE: The objective of this study was to check which initial dose of vancomycin is needed to achieve the therapeutic target that is currently used in pediatrics.
METHODS: The search was conducted in the following data sources: Pubmed (1980-2017), the Cochrane Library, and Embase (1986-2017) and the references of the published studies; searches were performed using the key terms: child, children, pediatrics, infants and adolescents, vancomycin, pharmacokinetics, and pharmacodynamics. The data extracted from the studies were analyzed and grouped using RevMan V 5.2 software. The confidence interval (CI) 95% and the odds ratio (OR) were calculated considering the Mantel-Haenszel random effect.
RESULTS: From the 704 studies identified, 40 revealed eligibility for this review and only 20 presented enough data to be included in the statistical analysis. The articles found in this review were published between 1980 and 2017. The vancomycin doses varied between 40 mg/kg/day to 120 mg/kg/day. The statistical tests demonstrated significant clinical heterogeneity of I2 (84%).
CONCLUSIONS: The meta-analysis study revealed in the majority of studies that doses lower than 60 mg/kg/day were not enough to achieve desirable vancomycin plasma concentrations "area under the curve in 24 h/minimum inhibitory concentration >400 (AUC0-24/MIC>400) or trough 10-20 mg/L" to control bacterial infections in pediatrics.

Entities:  

Keywords:  Pediatrics; Pharmacodynamics; Pharmacokinetics; Vancomycin

Mesh:

Substances:

Year:  2017        PMID: 28776198     DOI: 10.1007/s00228-017-2306-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  61 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

2.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.

Authors:  S H Downs; N Black
Journal:  J Epidemiol Community Health       Date:  1998-06       Impact factor: 3.710

3.  Pharmacokinetics of glycopeptide antibiotics in children.

Authors:  Hidekazu Ito; Nobuaki Shime; Tadashi Kosaka
Journal:  J Infect Chemother       Date:  2012-08-08       Impact factor: 2.211

4.  Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Yoshio Takesue; Norio Ohmagari; Takahiro Mochizuki; Hiroshige Mikamo; Masafumi Seki; Shunji Takakura; Issei Tokimatsu; Yoshiko Takahashi; Kei Kasahara; Kenji Okada; Masahiro Igarashi; Masahiro Kobayashi; Yukihiro Hamada; Masao Kimura; Yoshifumi Nishi; Yusuke Tanigawara; Toshimi Kimura
Journal:  J Infect Chemother       Date:  2013-05-15       Impact factor: 2.211

5.  Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.

Authors:  Cady Ploessl; Christopher White; Kalen Manasco
Journal:  Pediatr Infect Dis J       Date:  2015-10       Impact factor: 2.129

6.  Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.

Authors:  M L Glover; E Cole; J Wolfsdorf
Journal:  J Crit Care       Date:  2000-03       Impact factor: 3.425

7.  AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis.

Authors:  Shankar Lanke; Tian Yu; Joseph E Rower; Alfred H Balch; E Kent Korgenski; Catherine M Sherwin
Journal:  J Clin Pharmacol       Date:  2016-07-15       Impact factor: 3.126

8.  Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.

Authors:  D Chang
Journal:  Pediatr Infect Dis J       Date:  1995-08       Impact factor: 2.129

Review 9.  Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis.

Authors:  Zhi-Kang Ye; Hui-Lin Tang; Suo-Di Zhai
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

10.  A Prospective Study to Assess Vancomycin Serum Concentrations inPediatric Patients with Current Dosing Guidelines.

Authors:  Peyman Arfa; Abdollah Karimi; Sedigheh Rafiei Tabatabaei; Alireza Fahimzad; Shahnaz Armin; Mohammad Sistanizad
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

View more
  4 in total

Review 1.  Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin.

Authors:  Roopali Sharma; Margaret R Hammerschlag
Journal:  Curr Infect Dis Rep       Date:  2019-09-05       Impact factor: 3.725

2.  Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function.

Authors:  Chanika Chuphan; Waroonrat Sukarnjanaset; Thanyawee Puthanakit; Thitima Wattanavijitkul
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

Review 3.  The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.

Authors:  Stacey Tkachuk; Kyle Collins; Mary H H Ensom
Journal:  Paediatr Drugs       Date:  2018-04       Impact factor: 3.022

Review 4.  Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.

Authors:  Matylda Resztak; Joanna Sobiak; Andrzej Czyrski
Journal:  Pharmaceutics       Date:  2021-11-23       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.